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Abstract: 
Background and Purpose: Both intracerebral hemorrhage (ICH) and brain edema, have been attributed to 
reperfusion after IV thrombolysis. We explored the interaction of recanalization, and core size for imaging 
outcomes (ICH and vasogenic brain edema). 
Methods: In patients with anterior circulation occlusion given IV thrombolysis <4.5h and imaged with CT 
perfusion (CTP) and CT angiography (CTA), we defined volumes of core (relative Delay Time [rDT]>2s, 
relative cerebral blood flow<40%) and penumbra (rDT>2s). CT and CTA at 24h were reviewed for ICH 
(ECASS-2 definition), early vasogenic edema (IST-3 criteria), and recanalization (TIMI 2-3). Independent 
effects of recanalization, core volume and potential interactions on edema, ICH and day 90 outcomes were 
estimated by logistic regression.  
Results: In 123 patients, there was a trend for recanalization to be associated with H1/2 ICH, but not with 
PH1/2 ICH (OR 1.7 (0.33-8.8); p=0.5), any edema or Significant Brain Edema (SBE; OR 1.45 (0.4-4.9); 
p=0.55). Ischemic core (>50ml) was associated with any ICH (OR 4.0 (1.6-9.5); p=0.003), edema (OR 5.4 
(2-14); p<0.01), and SBE (OR 17.4 (5.3-57); p<0.01), but not PH1/2 ICH (OR 1.2 (0.23-6.5); p=0.8), after 
controlling for recanalization. There was no significant interaction of recanalization and large core for any 
adverse outcomes.  
Conclusions: Large ischemic core was associated with poorer outcomes and both early vasogenic brain 
oedema and ICH, but recanalization on 24h CTA was associated with clinically favourable outcome. There 
was no significant interaction of recanalization and large core volume for any outcomes.  The association 
of haemorrhage or brain edema with post-thrombolysis reperfusion is unclear.  
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Introduction: 
Intravenous (IV) thrombolysis <4.5h after onset significantly improves  outcome , but carries increased risk 
of intracerebral hemorrhage (ICH).1, 2 Reperfusion is proposed to be necessary both for ICH 3 and 
vasogenic brain edema4, the other major cause of early neurological deterioration after stroke. 
Both the third International Stroke Trial (IST-3), and subsequent pooled analysis of alteplase trials 5, 
indicated slight excess of fatal symptomatic ICH (SICH) within 7 days of treatment (2.7% compared to 
0.4% in IST-3)6. IST-37 also reported a small excess risk of fatal brain swelling (approximately 1.5%) 
within 7 days, and the Alteplase Summary of Medicinal Product Characteristics  
(https://www.medicines.org.uk/emc/medicine/308 section 4.4) states that “reperfusion of the ischemic area 
may induce cerebral oedema in the infarcted zone.” Vasogenic edema was associated with increased blood-
brain barrier permeability after reperfusion in a rodent transient global cerebral ischemia model8, 9, but 
complex interactions of severity and duration of ischemia, and timing of reperfusion confound this possible 
relationship10. Space-occupying cerebral edema is clinically associated with large artery occlusions that 
recanalize rarely with IV rtPA11, 12, and no excess risk of brain edema was reported in previous trials2, 13. 
Different types of hemorrhage may have different mechanisms and clinical implications: hemorrhagic 
infarction (HI1 or HI2 in the ECASS-2 classification13) may be an epiphenomenon of reperfusion with no 
adverse clinical implications, while, in contrast, parenchymal hematomas with independent mass effect 
(PH1 or PH2 13) are linked with clinical worsening and may be related to blood-brain barrier breakdown 
after reperfusion14. 
Imaging features may interact with treatment. The Diffusion and perfusion Imaging evaluation for 
understanding stroke evolution (DEFUSE)15study and combined analysis of DEFUSE and the Echoplanar 
Imaging Thrombolysis Evaluation Trial (EPITHET) studies 16found increased risk of PH1 or PH2 ICH 
when reperfusion occurred in patients with “large core” (large volumes of severely hypoperfused tissue on 
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MRI). Interaction of early reperfusion with other indices of severe ischemia (large DWI volumes,  17, 18, 
very low cerebral blood volume on perfusion imaging19 or poor collaterals20)  has been reported for SICH 
after IV thrombolysis. The extent of vasogenic edema may also interact with ischemic core volume (>50% 
hypodensity on CT was associated clinically with malignant brain edema  21)., and in an animal model  
reperfusion of large volumes of severely ischemic tissue (CBF <40%)  led to malignant edema22 . 
Previous studies have not investigated the relationship of imaging characteristics (e.g. ischemic core 
volume), reperfusion, and their interaction with brain edema and ICH after IV thrombolysis. We 
hypothesised that recanalization of large core (large ischemic area) would be associated with significant 
haemorrhage, and persistent occlusion with significant brain edema. 
 
Methods:  
We selected data from subjects treated with IV rtPA <4.5 hours after onset recruited at a single centre to 
one of three multimodal imaging studies during 2008-2013. Two studies were observational and one was a 
trial comparing aleplase and tenecteplase (ATTEST: NCT01472926)22, 23. In the two observational studies  
(one investigating feasibility of complex imaging, one investigating pathophysiology of acute 
hyperglycemia), all ischemic stroke patients aged >18 years and presenting < 6 hours after onset were 
eligible. Exclusion criteria were  contraindications to iodinated contrast  (allergy or estimated Glomerular 
Filtration Rate <30ml/min). In all studies, patients underwent CT, CT angiography and CT perfusion at 
baseline (<6h after onset) with follow-up brain CT and CTA (if occlusion was present on baseline imaging) 
approximately 24h later . Favourable outcome was defined as modified Rankin scale (mRS) 0-2 at final 
review (30 or 90 days, depending on individual study).  Endovascular treatment was not used. 
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Scans were acquired on a Philips Brilliance 64 multidetector scanner. Whole brain NCCT (5 mm slice 
thickness FOV 218 x 218 mm, 120 kv, 171 mA or 0·9 mm slice thickness, FOV 250x250  mm, 120 kV, 
404 mA) was followed by CTP with 40 mm slab coverage from the basal ganglia (8x5 mm slices, FOV 25 
cm, 80 kVp, 476 mA, 2 second cycle time, 30 cycles) using a 50 ml contrast bolus administered at 5 mls 
per second (350 Xenetix) via a large-gauge cannula. CTA covering aortic arch to the top of the lateral 
ventricles (0·67 mm slice thickness, 120 kV, 475 mA) was acquired during the first arterial passageof 
contrast (Xenetix 350, 60 mls, followed by 30 mls of saline bolus, both given at 5 ml per second) 
Imaging processing and analysis: 
Anonymised imaging studies were analysed independently by two researchers (BC, XH). CTP was 
processed offline using MiStar (Apollo Medical Imaging Technology, Melbourne, Australia). 
Deconvolution of tissue enhancement curves and arterial input function (AIF) selected from the anterior 
cerebral artery was performed using modified singular value decomposition (SVD) with compensation for 
the effects of arterial delay and dispersion. Delay time (DT) was determined by a delay-corrected SVD 
deconvolution by applying a series of delay time (DT) values, with actual delay time being minimum DT 
value, which produces Tmax=024.  Delay time and Tmax are related but are not identical, and since delay 
time is derived from a vascular transport model correcting for arterial delay and dispersion,  thresholds are 
smaller than Tmax23. Delay Time  has demonstrated superior correlation with tissue at risk in recent 
studies25. Cerebral Blood Flow (CBF) and Cerebral Blood Volume (CBV) were calculated from the peak 
height and area under tissue enhancement curves respectively, and Mean Transit Time (MTT) = CBV/CBF.  
Ischemic core was defined as tissue with relative CBF <40% of contralesional hemisphere and relative DT 
>2 sec; penumbra was defined as tissue with relative DT >2 sec but relative CBF e  40% of contralateral23.  
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To account for limited z axis coverage of CTP, we reduced the 70ml threshold used by EXTEND-IA23 and 
DEFUSE-226 proportionately, by dividing the mean of (Coregistered Infarct volume over 4cm/Total Infarct 
volume from whole brain NCCT) in the non-recanalized group: pproximately 70% of the total infarct was  
covered by the CTP slab, therefore we considered large core to be >50ml.We evaluated baseline NCCT for 
ASPECT scores27. 
CTA collaterals were graded if retrograde flow was seen on CTP source images, 28 and defined  as good 
(vessels reconstitute distal to the occlusion), moderate (vessels seen partially in ischemic territory), or poor 
(contrast opacification seen only in distal superficial branches).We modified Miteff’s classification to 
incorporate terminal ICA, M1, or M2 occlusion, (the original classification excluded M2 occlusion)28. 
 
Imaging Outcome Variables: 
On 24h NCCT, we classified ICH as per ECASS 2 criteria,13 and SICH as any ICH with increase in 
NIHSSe 4 points13. Any PH1 or PH2 were considered significant haemorrhage. Early vasogenic brain 
edema was classified as per IST-329 as no swelling (0), effacement of lateral ventricle (1), effacement of 
lateral plus 3rd ventricles (2), or midline shift (3): we defined grades 2-3 as Significant Brain Edema (SBE). 
Recanalization was defined as Thrombolysis in Myocardial Infarction (TIMI)30 grading 2- 3 at 24 hour 
follow up CT angiogram31.  
As an exploratory analysis, early major neurological improvement (NIHSS 0 or 1, or improvement by e8 
points by 24h) was taken as a biomarker of early reperfusion, and outcomes were compared among three 
groups – i) no recanalization on 24h CTA; ii) recanalization on 24h CTA but no early improvement 
(presumed late recanalization); and iii) recanalization on 24h CTA and early improvement, (presumed early 
recanalization).   
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Statistical Analysis: 
We compared groups by recanalization and ischemic core volume, using chi-squared tests or Fisher’s exact 
tests for categorical variables, and Mann-Whitney tests for continuous variables. We evaluated the 
independent effect sizes of recanalization, core volume and their interaction on imaging and clinical 
outcomes using logistic regression. Analyses used IBM SPSS Statistics (version 22).  
 
Results: 
Of 263 subjects, 159 had anterior circulation stroke with vessel occlusion pre-treatment; we excluded 24 
subjects presenting >4.5h after onset, and 12 in whom 24h CTA was not evaluable, leaving 123 subjects. 
Baseline collateral grading was available in a subset of 106 subjects. 
Median age was 74 years (IQR 62-80), median NIHSS 15 [IQR 9-20], and median symptom onset to 
treatment time 180min (IQR 151-210). Occlusion site was ICA or M1 in 84 (68%). Recanalization on 24h 
CTA was seen in 80 (66%) overall, with recanalization  in 30%, Tandem or proximal ICA, 74% of M1, 
87% of M2 and 50% of M3 occlusions ( online supplementary Table I).  Mean time interval from treatment 
to follow up imaging was 27.5 hrs (SD ±7). Detailed baseline characteristics are presented in Table.1.  
Tenecteplase was used in 31 patients and alteplase in 92. 
Most hemorrhages were HI1 or HI2 (28 (23%)) and there were few PH1 or PH2 (8 (6%)). There was a 
trend for recanalization to be associated with ICH of any class (28 (35%) v 8 (18%); p=0.06), 
predominantly HI1/HI2 (22 (27.5%) v 6 (14%); p=0.08), while incidence of PH1/PH2 did not differ (6 
(7.6%) v 2 (4.6%); p=0.5. Figure.1). Edema of any grade was less frequent with 24h recanalization, 
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although not significantly (32 (40%) v 23 (53%); p=0.15) and significant brain edema was not related to 
recanalization (12 (15%) v 6 (12%); p=0.8. See figure. 2). 
Neither significant edema (12/92 alterplase-treated versus 6/31 tenecteplase-treated , OR 0.6, 95% CI 0.2-
1.8; p=0.4), nor significant haemorrhage (8/92 alteplase-treated versus 0/31 tenecteplase-treated, p=0.2; 
odds ratio not calculable) was associated with thrombolytic agent. 
After adjusting for 24h recanalization, large core (>50ml) was associated with both hemorrhage and edema, 
most notably with SBE, although no significant relationship with PH1/PH2 ICH or SICH was evident. 
Recanalization was also associated with a trend towards any ICH, particularly HI1/2 ICH, but not to edema 
(Table 2). Regression analysis did not identify significant interaction of large core and 24h recanalization 
for any outcome (Table 2). Recanalization was associated with significantly reduced odds of death or 
dependence (mRS 3-6) at day 30 or 90, while large core volume was associated with increased odds of 
these outcomes. 
Early major improvement occurred in 36 patients: 45 had recanalized by 24h CTA but did not exhibit early 
major improvement, and 38 showed no recanalization and no early improvement. Edema and hemorrhagic 
outcomes were generally lower and day 90 excellent recovery better, in the group with presumed early 
recanalization but did not differ significantly between the late recanalizers and those with no recanalization 
(Table 3 and online Supplementary Table II). 
 
Discussion: 
 
Recent focus on potential hazards of IV rtPA highlights limited data on the interaction of patient 
characteristics, especially ischemic tissue volumes, reperfusion  and the pathophysiology of hemorrhage 
and  brain edema. Few patients have been studied with detailed brain imaging16, only a proportion of whom 
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have received thrombolytic therapy; animal models22, 32  may not recapitulate the human situation, and 
other data derive from series of  late endovascular intervention33.  
 
Our cohort allowed the study of interactions between 24h recanalization, perfusion characteristics and 
incidence of both ICH and early brain edema. We found  ICH incidence comparable to previous literature, 
for example ICH of all kinds in 34% (36/123) compared to 48% in ECASS-II, and SICH  in 5.7% (7/123) 
compared to7.7% in meta-analysis of thrombolysis trials6. Our incidence of  early vasogenic brain edema 
of any degree was 45% (55/123) and of SBE  6.8% (18/123) are comparable to reported figures for  edema8 
and for SBE (4% in tPA and 3% in control groups of IST-3)7 that used similar definitions, although other 
definitions yield variations in incidence 34. Our recanalization rate on 24h CTA (66% overall) was almost 
identical to that reported in the IMS-3 rtPA treated group, as were recanalization rates by occlusion site.35  
The major predictor of ICH and SBE in our study was the presence of a large “core”, defined by CTP 
thresholds and adjusted for limited z-axis coverage of our CTP protocol. This is consistent with a rodent 
study in which infarct volume, but not reperfusion, was associated with edema36. Older literature on 
reperfusion and post-ischemic edema in non-human primates examined only early time points (< 6 hours) 
of unclear  clinical relevance22, 37, 38. Recanalization in our study, in contrast, was associated only with a 
trend towards HI1/2  ICH. Neither recanalization, large core nor their interaction was associated with 
clinically relevant PH1/2 ICH. DEFUSE12 reported potential interaction of large core and early reperfusion 
in provoking SICH, and defined the “malignant profile” based on MRI features similar to the CTP features 
in our study. Of 6 DEFUSE subjects with the “malignant profile,”  3 experienced (uniformly fatal) SICH. 
The combined EPITHET and DEFUSE studies13  included only 27 “malignant profile” patients, of whom 
6/9 who reperfused developed PH1/2 ICH, compared to 2/18 without reperfusion. Despite similar patient 
numbers, we were unable to replicate this interaction. Since perfusion characteristics may better define ICH 
risk than diffusion-weighted MRI19, it seems unlikely that this is due to a difference between MRI and CT-
based tissue viability assessment methods. 
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As an exploratory analysis we assessed major early clinical improvement as a biomarker of early 
reperfusion. This group had significantly fewer ICH or edema events and greater probability of favourable 
day 90 outcome. The incidence of significant ICH or edema did not differ between those with presumed 
late recanalization and those without recanalization, but it is not possible to exclude a relationship between 
late recanalization and adverse imaging outcomes. 
 
Good clinical outcome was strongly associated with 24h recanalization (OR 2.8 (1.2-6.8); p=0.02) and was 
less likely with large core (OR 0.15 (0.04-0.5); p=0.03), consistent with previous observations39, but there 
was no significant interaction between these variables in predicting good 90 day outcome. This is 
consistent with the known prognostic value of both variables 39, 40, but also with the lack of interaction 
between endovascular treatment effect and CTP features.41 
 
Our study has limitations. As a single centre, retrospective analysis, independent replication in other 
settings is desirable. The small number of clinically significant hemorrhagic and brain swelling outcomes 
inevitably lead to wide confidence intervals around the effect estimates, encompassing the possibility that 
recanalization may be related to either significant edema or ICH, and means that conclusions must be 
cautious: nonetheless, with a larger number of outcome events we were unable to replicate earlier reports of 
an association with ICH, as discussed above. No classification of brain edema has been reported 
consistently in clinical studies, and different classification methods may yield different incidence. The 
timing of brain imaging for outcome assessment in our dataset (mean 27.5h after IV thrombolysis) is too 
early to detect maximal brain swelling, but while this might underestimate the severity of brain edema, it 
seems unlikely to underestimate the incidence of significant brain edema based on data that indicate that 
95% of cases progressing to malignant MCA infarction were identifiable on 24h CT34. CTP analysis was 
based on validated thresholds, but  standardisation is not yet agreed42. Since we had access to angiographic 
outcome data only at approximately 24h, we could not discriminate early from late recanalization, which 
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may carry different risks of ICH,43, 44 although we undertook exploratory analyses using early clinical 
improvement as a biomarker for this. In addition, recanalization does not necessarily lead to tissue 
reperfusion45, which is the more important parameter at tissue level46. We used TIMI 2-3 (partial or 
complete recanalization) since even partial restoration of flow might be expected to impact on adverse 
complications, whereas TIMI 3 would be more strongly related to favourable clinical outcomes, which was 
an endpoint of secondary interest in this study. The overall recanalization rate at 24h in our study (66%) 
matches that reported by the IMS-3 trialists (65%) based on a 24h CTA endpoint, with comparable 
individual occlusion site recanalization rates ,35 offering further reassurance about external validity.  
 
Our findings indicate  that 24h recanalization itself is not significantly associated with early vasogenic 
edema, or significant hemorrhage, questioning the widespread attribution of these outcomes to “reperfusion 
injury.” The association of large core with both significant edema, and also poor outcome in spite of 
recanalization, is consistent with recent clinical trial strategies that have sought to exclude such patients 
from reperfusion therapies. Observational data cannot define risk: benefit ratio, however, and it is 
important to bear in mind that excluding “large core” patients might represent an efficient clinical trial 
strategy, but that risk: benefit balance in this group remains to be determined: treatment in this group may 
still be associated with net benefit.  
 
Conclusions: Among patients treated with IV rtPA, 24h recanalization was not independently associated 
with significant early (24h) vasogenic edema or significant hemorrhage, although incidence of hemorrhagic 
infarction types 1 and 2 was higher. Large ischemic core was associated with both significant brain edema 
and poor outcome. There was no interaction of recanalization and large core lesions for any imaging 
outcomes. Early major clinical improvement as a marker of probable early reperfusion, was associated with 
lower incidence of both significant hemorrhage and edema. 
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Tables & Figures: 
Table1. Baseline characteristics of study population (n=123) 
Variables Recanalized (n=80) Occluded (n=43) P* 
Age (median (IQR), years) 73 (63-81) 74 (62-79) 0.8 
Male (n, %) 48 (60%) 21 (48.8%) 0.1 
NIHSS baseline(median, IQR) 15(9-19) 14(9-20) 0.6 
Onset to treatment time(median , IQR, 
min) 
175(145-210) 190(165-206) 0.6 
ASPECT score (median, IQR) 7(5-9) 7(5-9) 0.9 
Occlusion Site:   <0.01 
ICA/tandem (n, %) † 9 (11.3%) 21 (48.8%)  
M1 (n, %) † 40 (50%) 14 (32.6%)  
M2 (n, %) † 27 (33.8%) 4 (9.3%)  
M3 (n, %) † 4 (5%) 4 (9.3%)  
Cardioembolic (n, %) Â 34(47.9%) 16 (39%) 0.7 
TACI (n, %) § 54 (67.5%) 30 (69.8%) 0.7 
Atrial Fibrillation (n, %) 35 (47.9%) 14 (33.3%) 0.17 
Diabetes (n, %) 8 (10%) 5 (11.6%) 0.7 
History of Stroke or Transient Ischemic 
attack (n, %) 
14 (18%) 7 (16.3%) 1.0 
Hypertension (n, %) 45 (56.3%) 26 (62%) 0.5 
Smoker (n, %) 23 (28.8%) 14 (32.6%) 0.3 
On anti platelets (n, %) 42 (52.5%) 24 (55.8%) 0.8 
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Imaging  outcomes in relation to recanalization within small or large core groups (n=122)Á 
 Core small(<50ml) (n=95) Core large(>50ml) (n=27) p 
ICA or M1 
occlusion† 
57(69%) 26(96%) <0.001 
Poor (vs.  
good or 
moderate) 
collaterals  
9/78(11.5%) 12/22(54.5%) <0.01 
Poor 
outcome 
(mRS 3-6 at 
30 or 90 
days) 
51(54%) 24(89%) 0.001 
 Recanalize
d (n=63 ) 
Occluded(n
=32) 
P value Recanalized 
(n=16) 
Occluded(
n=11) 
 
P value 
Any ICH (n, 
%) 
19 (30%) 4 (12%) 0.06 8 (50%) 4 (36%) 0.5 
 
HI1 or HI2 
(vs. no ICH, 
PH1, PH2) 
14 (22%) 3 (9.4%) 0.16 7 (44%) 3 (27%) 0.4 
Type of 
hemorrhage
     0.25 
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# 
No ICH (n, 
%) # 
44 (70%) 28 (87%) 0.35 8 (50%) 7 (63.6%)  
HI1 (n, %) 
# 
5 (8%) 2 (6%)  3 (19%) 3 (27%)  
HI2 (n, %) 
# 
9 (14%) 1 (3%)  4 (25%) 0 (0%)  
PH1 (n, %) 
# 
1 (1.6%) 0 (0%)  0 (0%) 1 (9%)  
PH2 (n, %) 
# 
4 (6%) 1 (3%)  1 (6%) 0 (0%)  
Any edema 
(n, %) 
19 (31%) 15 (47%) 0.13 12 (75%) 8 (73%) 0.9 
Edema 
type** 
     0.38 
No edema 
(n, %)** 
44 (70%) 17 (53%) 0.17 4 (25%) 3 (27%)  
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Effacement 
of lateral 
ventricle (n, 
%)** 
16 (25%) 13 (40%)  3 (19%) 4 (36%)  
Effacement 
of lateral 
ventricle 
and 3rd 
ventricle (n, 
%)** 
2 (3%) 0 (0%)  6 (37.5%) 1 (9%)  
Midline 
shift (n, 
%)** 
1 (1.6%) 2 (6.3%)  3 (19%) 3 (27%)  
SICH 
(ECASS-2) 
(n, %) # 
4 (6%) 1 (3%) 0.5 0 2(18%) 0.07 
Significant 
ICH (n, %) 
5 (8%) 1 (3%) 0.36 1 (6%) 1 (9%) 0.8 
SBE (n, %) 
†† 
3 (5%) 2 (6%) 0.7 9 (56%) 4 (36%) 0.3 
Poor 20 (47%) 22 (69%) 0.04 13 (81%) 11 0.13 
19 
 
outcome at 
30 d or 90d 
(mRS>2) 
(n, %) 
(100%) 
 
* Chi-square test or Fisher test  for categorical variables, Mann-whitney U test for continuous 
variables 
ASPECT score: Alberta stroke Early CT Score 
† ICA-Internal Carotid artery, M1,M2,M3- branches of Middle cerebral artery 
Â Cardio embolic versus other aetiologies (large artery atherosclerosis, lacunar stroke, unknown cause) 
§ Total anterior circulation Infarction(TACI) versus other stroke types ( Oxford stroke classification) 
Á one subject out of total study population (n=123)did not have core size available  
#Hemorrhage classification according to ECASS-2 criteria 
** Brain edema classification by Wardlaw&Sellar criteria 
††SBE: Significant Brain Edema 
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Table 2: Regression for association of large core and recanalization, and their interaction, for imaging and clinical outcomes 
 Any ICH* HI1 or HI2† 
 
Significant 
ICH* 
 
SICHÂ Any edema 
 
SBE§ 
 
Good  90d 
mRS (0-2) 
Large core (OR 
(95% CI); p) 
 
4 (1.6-
9.5); 
p=0.003 
2.9 (1.13-
7.8); p=0.03 
 
1.2 (0.23-
6.5); p=0.8 
1.6 (0.3-
8.5); p=0.6 
5.4 (2-14); 
p<0.01 
17.4 (5.3-
57); 
p<0.01 
0.15 (0.04-
0.5); p=0.03  
Recanalization 
(OR (95% CI); 
p) 
 
2.3 (0.97-
5.5); 
p=0.06 
 2.5 (0.9-
6.9); p=0.08 
1.7 (0.33-
8.8); p=0.5 
0.8 (0.17-
3.8); p=0.8 
0.5 (0.27-
1.18); 
p=0.13 
1.45 (0.4-
4.9); 
p=0.55 
2.8 (1.2-6.8); 
p=0.02 
Large core * 
Recanalization 
(OR (95%CI); 
0.34 
(0.05-2.2); 
p=0.26 
0.7 (0.09-6); 
p=0.8 
0.25 
(0.007-9); 
p=0.45 
p=1Á 1.7 (0.2-
11); p=0.56 
3(0.2-34) 
 p=0.37 
p=0.99# 
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p) 
* ICH Intracerebral hemorrhage,   Hemorrhagic infarction type 1 or 2, Â Symptomatic Intracerebral hemorrhage, § 
Significant Brain Edema, Á Since 0% of recanalized group in large core has SICH, the corresponding odds ratios cannot be 
calculated,# since 100% of occluded group in large core have poor 90dmRS, the corresponding odds ratios cannot be 
calculated. 
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Table.3: Comparison of early improvers with non-early improvers 
 Early 
improvement 
(n=36) 
No early 
improvement/Recanalized 
(n=45) 
No early  
improvement/Non-
recanalized (n=38) 
P value§ 
Any ICH 5 (14%) 19 (42%) 9 (24%) 0.014 
Significant 
ICH 
1 (3%) 5 (11%) 2 (5%) 0.3 
SICH* 0 3 (7%) 3 (8%) 0.25 
Any edema 7 (19%) 24 (53%) 21 (55%) 0.002 
SBE 2 (5.6%) 10 (22%) 6 (16%) 0.11 
Good 90d 
mRS 
22 (63%) 12 (27%) 10 (26%) 0.001 
ICH: Intracerebral hemorrhage 
*SICH as per ECASS-2 criteria 
SBE: Significant brain edema 
§ chi-square values 
 
 
 
